Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 6/20 | 0.43 |
| ▸ | TP53 | P04637 | 6/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | CLPP | Q16740 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22845225 | 0.92 | MAPT (0.46) | P2RX3TP53KDM1AHDAC1HDAC6 | |
| SCHEMBL22717340 | 0.91 | P2RX3 (0.41) | P2RX3TP53KDM1AHDAC1HDAC6 | |
| SCHEMBL22717413 | 0.87 | KDM1A (0.47) | P2RX3TP53KDM1AHDAC1HDAC6 | |
| SCHEMBL22845439 | 0.84 | LMNA (0.44) | TP53CLPPMAPTKDM4E | |
| SCHEMBL29670369 | 0.82 | P2RX3 (0.38) | P2RX3TP53KDM1AMAPT | |
| SCHEMBL22718494 | 0.82 | P2RX3 (0.47) | P2RX3TP53KDM1AHDAC1HDAC6 | |
| SCHEMBL24484016 | 0.80 | P2RX3 (0.36) | P2RX3TP53KDM1AHDAC1HDAC6 | |
| SCHEMBL22845477 | 0.79 | P2RX3 (0.46) | P2RX3TP53HDAC1HDAC6 | |
| SCHEMBL24469837 | 0.78 | P2RX3 (0.41) | P2RX3TP53HDAC1HDAC6MAPT | |
| SCHEMBL24469807 | 0.77 | P2RX3 (0.43) | P2RX3HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220000874-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2022-01-06 | — | — | US | disclosed |
| US-11136321-B2 | Tricyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2021-10-05 | — | — | US | disclosed |
| US-20200407361-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2020-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220000874-A1 | TRICYCLIC COMPOUNDS | SLC10A1, PKD1, CEL | P2RX3 3237/4885TP53 1710/4885KDM1A 4366/4885 |
| US-11136321-B2 | Tricyclic compounds | SLC10A1, PKD1, CEL | P2RX3 3237/4885TP53 1710/4885KDM1A 4366/4885 |
| US-20200407361-A1 | TRICYCLIC COMPOUNDS | SLC10A1, PKD1, CEL | P2RX3 3237/4885TP53 1710/4885KDM1A 4366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.